NASDAQ:MSLE Satellos Bioscience (MSLE) Stock Price, News & Analysis $9.32 -0.36 (-3.72%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$9.32 0.00 (0.00%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsFDA EventsNews and TrendsOwnershipSEC FilingsShort Interest About Satellos Bioscience Stock (NASDAQ:MSLE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Satellos Bioscience alerts:Sign Up Key Stats Today's Range$9.31▼$9.7550-Day Range$8.35▼$10.1952-Week Range$5.30▼$13.39Volume19,815 shsAverage Volume26,693 shsMarket Capitalization$197.77 millionP/E RatioN/ADividend YieldN/APrice Target$19.75Consensus RatingModerate Buy Company Overview Satellos Bioscience Inc. is a biotechnology company focused on developing regenerative medicines for conditions involving skeletal muscle damage, degeneration, or impaired repair. The company’s research is based on the role of muscle stem cells, also known as satellite cells, in maintaining and regenerating muscle tissue. Satellos’ lead product candidate is SAT-3247, an orally administered small-molecule therapy designed to enhance the activation and function of muscle stem cells. The company is evaluating this approach for potential use in diseases characterized by progressive muscle weakness, including Duchenne muscular dystrophy and other muscle disorders. Satellos Bioscience is headquartered in Vancouver, British Columbia, and is developing its therapies for international pharmaceutical and biotechnology markets. The company’s programs remain investigational, and their safety and effectiveness have not been established for marketing use.AI Generated. May Contain Errors. Read More Satellos Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreMSLE MarketRank™: Satellos Bioscience scored higher than 37% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingSatellos Bioscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialSatellos Bioscience has a consensus price target of $19.75, representing about 111.9% upside from its current price of $9.32.Amount of Analyst CoverageSatellos Bioscience has only been the subject of 2 research reports in the past 90 days.Read more about Satellos Bioscience's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Satellos Bioscience are expected to decrease in the coming year, from ($2.08) to ($2.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Satellos Bioscience is -4.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSatellos Bioscience has a P/B Ratio of 5.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.68% of the float of Satellos Bioscience has been sold short.Short Interest Ratio / Days to CoverSatellos Bioscience has a short interest ratio ("days to cover") of 4.28.Change versus previous monthShort interest in Satellos Bioscience has recently decreased by 2.84%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSatellos Bioscience does not currently pay a dividend.Dividend GrowthSatellos Bioscience does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Satellos Bioscience this week, compared to 3 articles on an average week.MarketBeat Follows3 people have added Satellos Bioscience to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Satellos Bioscience insiders have not sold or bought any company stock.Percentage Held by Insiders37.90% of the stock of Satellos Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsSatellos Bioscience has minimal institutional ownership at this time.Read more about Satellos Bioscience's insider trading history. Receive MSLE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Satellos Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MSLE Stock News HeadlinesSatellos Bioscience to Showcase Forazapadin Program at World Muscle Society CongressSeptember 15, 2026 | tipranks.comSatellos to Present at the 31st Annual Congress of the World Muscle SocietySeptember 15, 2026 | markets.businessinsider.comA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the country entirely - as concerns grow about the next phase of the AI market. One AI insider says investors should reassess their positions before September 30, pointing to a critical shift ahead for tech and AI-related stocks.September 20 at 1:00 AM | TradeSmith (Ad)Satellos Names Forazapadin As INN For Lead DMD Drug CandidateSeptember 9, 2026 | rttnews.comSatellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247September 9, 2026 | markets.businessinsider.comLifeSci Capital Sticks to Their Buy Rating for Satellos Bioscience (MSLE)September 2, 2026 | theglobeandmail.comSatellos to Participate in Upcoming Investor ConferencesSeptember 1, 2026 | financialpost.comFSatellos Bioscience IncJuly 30, 2026 | cnn.comSee More Headlines MSLE Stock Analysis - Frequently Asked Questions How have MSLE shares performed this year? Satellos Bioscience's stock was trading at $11.27 on February 12, 2026. Since then, MSLE stock has decreased by 17.3% and is now trading at $9.32. How were Satellos Bioscience's earnings last quarter? Satellos Bioscience Inc. (NASDAQ:MSLE) posted its quarterly earnings results on Thursday, August, 13th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by $0.18. Who are Satellos Bioscience's major shareholders? Satellos Bioscience's top institutional shareholders include Stonepine Capital Management LLC (2.36%), AWM Investment Company Inc. (1.46%) and Empery Asset Management LP (0.51%). How do I buy shares of Satellos Bioscience? Shares of MSLE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/13/2026Today9/20/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:MSLE CIK1421642 Websatellos.com Phone(647) 660-1780Fax604-602-9699Employees18Year FoundedN/APrice Target and Rating Average Price Target for Satellos Bioscience$19.75 High Price Target$23.00 Low Price Target$18.00 Potential Upside/Downside+111.9%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$24.87 million Net MarginsN/A Pretax MarginN/A Return on Equity-71.97% Return on Assets-65.80% Debt Debt-to-Equity RatioN/A Current Ratio11.22 Quick Ratio11.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.80 per share Price / Book5.18Miscellaneous Outstanding Shares21,220,000Free Float13,175,000Market Cap$197.77 million OptionableN/A Beta1.53 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:MSLE) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredNVDA CEO says it’s a "once-in-a-generation opportunity"NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...Monument Traders Alliance | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredIran War: Why Is Trump Protecting THEM?A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military prote...Banyan Hill Publishing | SponsoredNew Form of AI Could Ignite the ‘Great Wealth Rotation’Marc Chaikin, a 60-year Wall Street veteran who worked alongside Paul Tudor Jones and Steve Cohen, says a new ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Satellos Bioscience Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Satellos Bioscience With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
